OBI Pharma: An Exciting Launching Pad for Young Scientists

OBI Pharma (4174.TWO) showcased at BIO Asia–Taiwan 2024 on July 29th how it leverages its deep glycoscience expertise to continually seek breakthroughs in cancer treatment. OBI aims to overcome the challenges of cancer treatment, such as side effects and drug resistance, by providing solutions to address the unmet medical needs for cancer patients with first-in-class or best-in-class new drugs.